Incidence, management, and prevention of perioperative complications of greenlight hps TM laser photoselective vaporization prostatectomy: Experience in the first 70 patients

Massimiliano Spaliviero, Motoo Araki, Daniel J. Culkin, Carson Wong

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Purpose: We report the incidence, prevention, and management of perioperative adverse events in patients treated with GreenLight HPS™ laser photoselective vaporization prostatectomy (PVP). Materials and Methods: A side-firing GreenLight HPS™ laser system was used to perform transurethral PVP. American Urological Association Symptom Score, Quality of Life score, Sexual Health Inventory for Men score, serum prostate-specific antigen (PSA), maximum flow rate (Qmax), and postvoid residual were assessed preoperatively and at 1, 4, 12, 24, and 52 weeks postsurgery. Preoperative and 3-month postsurgery volumetric prostate measurements with transrectal ultrasonography, operative times (laser and total), and energy usage were recorded. Serum PSA was obtained at the 12- and 52-week visit. Adverse events were recorded perioperatively and at each follow-up interval. Results: Seventy consecutive patients with a median age of 67 (45-87) years, median prostate volume of 61.6 (20.9-263.0) mL, and median PSA of 1.4 (0.1-10.1) ng/mL underwent GreenLight HPS™ laser PVP from July 2006 through March 2008. All procedures were performed in an outpatient setting, with a mean laser time of 13 (3-34) minutes, mean total operative time of 30 (6-100) minutes, and mean energy usage of 85 (11-235) kJ. Perioperative complications included intraoperative bleeding (1.4%), postoperative clinically nonsignificant hematuria (78.5%), hematuria requiring clot evacuation (1.4%), urinary retention requiring recatheterization (2.8%), urinary tract infection (4.3%), and prostatitis (1.4%). No urethral strictures, bladder neck contracture, or urinary incontinence were noted. Conclusions: GreenLight HPS™ laser PVP appears to have a low incidence of perioperative adverse events.

Original languageEnglish
Pages (from-to)495-502
Number of pages8
JournalJournal of Endourology
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 1 2009
Externally publishedYes

Fingerprint

Laser Therapy
Prostatectomy
Prostate-Specific Antigen
Lasers
Incidence
Hematuria
Operative Time
Prostate
Urethral Stricture
Prostatitis
Volatilization
Urinary Retention
Intraoperative Complications
Reproductive Health
Urinary Incontinence
Contracture
Serum
Urinary Tract Infections
Ultrasonography
Urinary Bladder

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Incidence, management, and prevention of perioperative complications of greenlight hps TM laser photoselective vaporization prostatectomy : Experience in the first 70 patients. / Spaliviero, Massimiliano; Araki, Motoo; Culkin, Daniel J.; Wong, Carson.

In: Journal of Endourology, Vol. 23, No. 3, 01.03.2009, p. 495-502.

Research output: Contribution to journalArticle

@article{02905d9ebbe24380af7e5cdb0e64bec9,
title = "Incidence, management, and prevention of perioperative complications of greenlight hps TM laser photoselective vaporization prostatectomy: Experience in the first 70 patients",
abstract = "Purpose: We report the incidence, prevention, and management of perioperative adverse events in patients treated with GreenLight HPS™ laser photoselective vaporization prostatectomy (PVP). Materials and Methods: A side-firing GreenLight HPS™ laser system was used to perform transurethral PVP. American Urological Association Symptom Score, Quality of Life score, Sexual Health Inventory for Men score, serum prostate-specific antigen (PSA), maximum flow rate (Qmax), and postvoid residual were assessed preoperatively and at 1, 4, 12, 24, and 52 weeks postsurgery. Preoperative and 3-month postsurgery volumetric prostate measurements with transrectal ultrasonography, operative times (laser and total), and energy usage were recorded. Serum PSA was obtained at the 12- and 52-week visit. Adverse events were recorded perioperatively and at each follow-up interval. Results: Seventy consecutive patients with a median age of 67 (45-87) years, median prostate volume of 61.6 (20.9-263.0) mL, and median PSA of 1.4 (0.1-10.1) ng/mL underwent GreenLight HPS™ laser PVP from July 2006 through March 2008. All procedures were performed in an outpatient setting, with a mean laser time of 13 (3-34) minutes, mean total operative time of 30 (6-100) minutes, and mean energy usage of 85 (11-235) kJ. Perioperative complications included intraoperative bleeding (1.4{\%}), postoperative clinically nonsignificant hematuria (78.5{\%}), hematuria requiring clot evacuation (1.4{\%}), urinary retention requiring recatheterization (2.8{\%}), urinary tract infection (4.3{\%}), and prostatitis (1.4{\%}). No urethral strictures, bladder neck contracture, or urinary incontinence were noted. Conclusions: GreenLight HPS™ laser PVP appears to have a low incidence of perioperative adverse events.",
author = "Massimiliano Spaliviero and Motoo Araki and Culkin, {Daniel J.} and Carson Wong",
year = "2009",
month = "3",
day = "1",
doi = "10.1089/end.2008.0299",
language = "English",
volume = "23",
pages = "495--502",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Incidence, management, and prevention of perioperative complications of greenlight hps TM laser photoselective vaporization prostatectomy

T2 - Experience in the first 70 patients

AU - Spaliviero, Massimiliano

AU - Araki, Motoo

AU - Culkin, Daniel J.

AU - Wong, Carson

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Purpose: We report the incidence, prevention, and management of perioperative adverse events in patients treated with GreenLight HPS™ laser photoselective vaporization prostatectomy (PVP). Materials and Methods: A side-firing GreenLight HPS™ laser system was used to perform transurethral PVP. American Urological Association Symptom Score, Quality of Life score, Sexual Health Inventory for Men score, serum prostate-specific antigen (PSA), maximum flow rate (Qmax), and postvoid residual were assessed preoperatively and at 1, 4, 12, 24, and 52 weeks postsurgery. Preoperative and 3-month postsurgery volumetric prostate measurements with transrectal ultrasonography, operative times (laser and total), and energy usage were recorded. Serum PSA was obtained at the 12- and 52-week visit. Adverse events were recorded perioperatively and at each follow-up interval. Results: Seventy consecutive patients with a median age of 67 (45-87) years, median prostate volume of 61.6 (20.9-263.0) mL, and median PSA of 1.4 (0.1-10.1) ng/mL underwent GreenLight HPS™ laser PVP from July 2006 through March 2008. All procedures were performed in an outpatient setting, with a mean laser time of 13 (3-34) minutes, mean total operative time of 30 (6-100) minutes, and mean energy usage of 85 (11-235) kJ. Perioperative complications included intraoperative bleeding (1.4%), postoperative clinically nonsignificant hematuria (78.5%), hematuria requiring clot evacuation (1.4%), urinary retention requiring recatheterization (2.8%), urinary tract infection (4.3%), and prostatitis (1.4%). No urethral strictures, bladder neck contracture, or urinary incontinence were noted. Conclusions: GreenLight HPS™ laser PVP appears to have a low incidence of perioperative adverse events.

AB - Purpose: We report the incidence, prevention, and management of perioperative adverse events in patients treated with GreenLight HPS™ laser photoselective vaporization prostatectomy (PVP). Materials and Methods: A side-firing GreenLight HPS™ laser system was used to perform transurethral PVP. American Urological Association Symptom Score, Quality of Life score, Sexual Health Inventory for Men score, serum prostate-specific antigen (PSA), maximum flow rate (Qmax), and postvoid residual were assessed preoperatively and at 1, 4, 12, 24, and 52 weeks postsurgery. Preoperative and 3-month postsurgery volumetric prostate measurements with transrectal ultrasonography, operative times (laser and total), and energy usage were recorded. Serum PSA was obtained at the 12- and 52-week visit. Adverse events were recorded perioperatively and at each follow-up interval. Results: Seventy consecutive patients with a median age of 67 (45-87) years, median prostate volume of 61.6 (20.9-263.0) mL, and median PSA of 1.4 (0.1-10.1) ng/mL underwent GreenLight HPS™ laser PVP from July 2006 through March 2008. All procedures were performed in an outpatient setting, with a mean laser time of 13 (3-34) minutes, mean total operative time of 30 (6-100) minutes, and mean energy usage of 85 (11-235) kJ. Perioperative complications included intraoperative bleeding (1.4%), postoperative clinically nonsignificant hematuria (78.5%), hematuria requiring clot evacuation (1.4%), urinary retention requiring recatheterization (2.8%), urinary tract infection (4.3%), and prostatitis (1.4%). No urethral strictures, bladder neck contracture, or urinary incontinence were noted. Conclusions: GreenLight HPS™ laser PVP appears to have a low incidence of perioperative adverse events.

UR - http://www.scopus.com/inward/record.url?scp=65549146756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549146756&partnerID=8YFLogxK

U2 - 10.1089/end.2008.0299

DO - 10.1089/end.2008.0299

M3 - Article

C2 - 19265468

AN - SCOPUS:65549146756

VL - 23

SP - 495

EP - 502

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 3

ER -